Crescent Biopharma, Inc.
CBIONASDAQHealthcareBiotechnology
As of Oct 23, 2026 close
- Market cap
- $428.47M
- P/E (TTM)
- -
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $8.72$27.41
- Volume (live)
- -
- Avg. volume (3M)
- 459.93K
Crescent Biopharma (CBIO) Stock Price & Financial Analysis
Crescent Biopharma Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $12.62 - $13.36 |
|---|---|
| 52-Week High | $27.41 |
| 52-Week Low | $8.72 |
| Open | $13.36 |
| Volume (last close) | 397.81K |
| Average Volume (3M) | 459.93K |
| Revenue (TTM) | 11.88M |
|---|---|
| Net Income (TTM) | -165.12M |
| Free Cash Flow (TTM) | -153.62M |
| EPS (TTM) | −$6.39 |
| Profit Margin | -1389.58% |
| Operating Margin | -1417.74% |
| Return on Equity (ROE) | -101.14% |
| Debt to Equity | 0.01 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Last Dividend Ex-Date | Jan 13, 2023 |
| Market Cap | 428.47M |
|---|---|
| Shares Outstanding | 33.42M |
| Price to Sales (P/S) | 36.06 |
| Price to Book (P/B) | 2.62 |
| EV/EBITDA | -1.61 |
| 50-Day MA | $16.19 |
|---|---|
| 200-Day MA | $15.80 |
| 1-Year Change | +2.74% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Crescent Biopharma at a Glance
As of the Oct 23, 2026 close, Crescent Biopharma (CBIO) has a market capitalization of $428.47M. The stock trades at 36.1× sales. Over the trailing twelve months it lost $165.12M on revenue of $11.88M and burned $153.62M of free cash flow.
As of its latest reported balance sheet, it holds $171.59M in cash and securities against $1.44M of debt, a net cash position of $170.16M.
Crescent Biopharma does not currently pay a dividend.
The share price is up 2.7% over the past year. At $12.82 (the Oct 23, 2026 close) it sits within its 52-week range of $8.72 to $27.41, below its 200-day moving average of $15.80.
Based on 6 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $30.17, 135.3% above the Oct 23, 2026 close.
Frequently Asked Questions About Crescent Biopharma
What is the current stock price for CBIO?
As of the Oct 23, 2026 close, CBIO stock trades at $12.82. The 52-week range is $8.72–$27.41, with a day range of $12.62–$13.36.
What is the P/E ratio for CBIO?
The P/E ratio (Price-to-Earnings) for CBIO is shown in the Key Statistics section. This valuation metric helps compare Crescent Biopharma, Inc. to industry peers.
Does CBIO pay dividends?
Crescent Biopharma does not currently pay a regular dividend. It reported a net loss over the trailing twelve months, so it has no earnings to distribute. Check the Dividends tab for historical dividend information.
What do analysts recommend for CBIO?
Based on ratings from 6 professional analysts over the last 90 days, the consensus for CBIO is Buy. The average 12-month price target is $30.17, a 135.3% upside from the Oct 23, 2026 close of $12.82.
What is the market cap of CBIO?
As of the Oct 23, 2026 close, Crescent Biopharma's market capitalization is $428.5M, classifying it as a small-cap company. Crescent Biopharma operates in the Healthcare sector within the Biotechnology industry.